Moderna (MRNA)
(Delayed Data from NSDQ)
$63.16 USD
-0.77 (-1.20%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $63.15 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.16 USD
-0.77 (-1.20%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $63.15 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Biogen (BIIB) Q2 Earnings & Sales Beat, 2024 Guidance Raised
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. It raises EPS guidance and revenue growth expectations for 2024.
Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash
by Zacks Equity Research
Moderna (MRNA) beats expectations for earnings and sales. Management cuts sales guidance by $0.5-$1.0 billion on concerns about competition for its marketed products and low sales in the EU.
Moderna (MRNA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Moderna (MRNA) delivered earnings and revenue surprises of 4.03% and 92.92%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Watch These 5 Biotech Stocks for Q2 Earnings: Beat or Miss?
by Ekta Bagri
Let's focus on biotech stocks like GSK, VRTX, BIIB, MRNA and REGN, which are scheduled to report this week.
Zacks Industry Outlook Highlights Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics
by Zacks Equity Research
Moderna, Sarepta Therapeutics, Halozyme Therapeutics, Krystal Biotech and Axsome Therapeutics have been highlighted in this Industry Outlook article.
Vertex (VRTX) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Ahan Chakraborty
Vertex's (VRTX) second-quarter revenues are expected to have been driven by the robust sales of its lead CF product, Trikafta/Kaftrio.
5 Biotech Stocks to Bet On Bright Industry Prospects
by Ekta Bagri
New drug approvals and strong pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position MRNA, SRPT, HALO, KRYS and AXSM well in this volatile sector.
Exploring Analyst Estimates for Moderna (MRNA) Q2 Earnings, Beyond Revenue and EPS
by Zacks Equity Research
Beyond analysts' top -and-bottom-line estimates for Moderna (MRNA), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2024.
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
by Sundeep Ganoria
Investors will likely focus on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates when it reports second-quarter earnings.
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Beam Therapeutics (BEAM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?
by Kinjel Shah
Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.
Why Moderna (MRNA) Dipped More Than Broader Market Today
by Zacks Equity Research
The latest trading day saw Moderna (MRNA) settling at $121.25, representing a -1.02% change from its previous close.
Novavax's (NVAX) Shares Surge 211% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Novavax's (NVAX) shares continue to soar thanks to the recently signed partnership with Sanofi (SNY) to market its COVID-19 vaccine and develop novel COVID-19-influenza combination vaccines.
Top Research Reports for Amazon.com, Prologis & Infosys
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Prologis, Inc. (PLD) and Infosys Limited (INFY), as well as a micro-cap stock Blue Dolphin Energy Company (BDCO).
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Backlog Conversion Likely to Aid Medpace's (MEDP) Q2 Earnings
by Zacks Equity Research
Continued strength in backlog conversion rate is likely to have boosted Medpace's (MEDP) top line in the second quarter.
Moderna (MRNA) Stock Moves -0.93%: What You Should Know
by Zacks Equity Research
Moderna (MRNA) closed the most recent trading day at $123.98, moving -0.93% from the previous trading session.
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs
by Kinjel Shah
J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.
Merck (MRK) Up 17% YTD on Keytruda Strength: Should You Buy?
by Kinjel Shah
Merck (MRK) stock is being driven by the strong sales of key products like Keytruda and Gardasil and positive pipeline and regulatory developments.
Moderna (MRNA) Stock Rises 22% YTD: Time to Buy the Stock?
by Sundeep Ganoria
Shares of Moderna (MRNA) continue to soar thanks to the encouraging development of its non-COVID pipeline. The company's potential product launches over the next few years make it worth looking at.
Should Direxion NASDAQ-100 Equal Weighted Index Shares (QQQE) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for QQQE
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why
by Zacks Equity Research
Moderna (MRNA) reachead $116.07 at the closing of the latest trading day, reflecting a -0.33% change compared to its last close.
Play Likely Earnings Beat With 5 Top-Ranked Stocks
by Sanghamitra Saha
Top-ranked stocks Chewy (CHWY), Wingstop (WING), Moderna (MRNA), Tenet Healthcare (THC) and Kinross Gold (KGC) are likely to beat on the bottom line in their upcoming releases.
Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RSPH)?
by Zacks Equity Research
Sector ETF report for RSPH
Biotech Stock Roundup: GSK, CVAC Revise Agreement, Updates From MRNA, RNAC & More
by Zacks Equity Research
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.